PEG-MGF vs Dulaglutide
Side-by-side comparison of key properties, dosing, and research.
Anabolic & IGF
PEG-MGFGLP-1 / Weight Loss Agonists
Dulaglutide- Summary
- PEG-MGF (Pegylated Mechano Growth Factor) is a modified form of MGF (Mechano Growth Factor) where polyethylene glycol (PEG) chains have been attached to extend its half-life from minutes to days. Native MGF is released locally in muscle in response to mechanical stress and quickly degrades. PEGylation allows systemic administration with sustained circulation, enabling whole-body muscle repair and anabolic signaling rather than the purely local effect of native MGF.
- Dulaglutide (brand name Trulicity) is a once-weekly GLP-1 receptor agonist approved by the FDA for type 2 diabetes management and cardiovascular risk reduction. It consists of two GLP-1 analog chains fused to a modified IgG4 Fc fragment, extending its half-life to approximately 5 days. While primarily a diabetes medication, it produces meaningful weight loss and has established cardiovascular outcomes data from the REWIND trial.
- Half-Life
- ~3 days (due to PEGylation)
- ~5 days
- Admin Route
- SubQ
- SubQ
- Research
- —
- —
- Typical Dose
- 200–400 mcg
- 0.75 mg → 1.5 mg
- Frequency
- 2–3x per week
- Once weekly
- Key Benefits
- Extended half-life (~3 days) vs native MGF (minutes)
- Systemic muscle satellite cell activation via subcutaneous injection
- Promotes muscle fiber repair and hypertrophy throughout the body
- Enhanced recovery from intense training or muscle injury
- Synergistic with IGF-1 LR3 and growth hormone peptides
- Useful in sarcopenia, post-injury recovery, and athletic performance
- Single injection provides multi-day anabolic signaling
- FDA-approved for type 2 diabetes
- Once-weekly subcutaneous dosing via auto-injector pen
- Reduces HbA1c by approximately 1.1–1.6%
- Modest weight loss of 1.5–3 kg at approved doses
- Demonstrated cardiovascular risk reduction (REWIND trial)
- Established long-term safety profile
- Renal protective effects in CKD
- Side Effects
- Water retention and localized swelling
- Potential hypoglycemia at high doses
- Theoretical cancer growth risk (growth factor)
- Injection site reactions
- +1 more
- Nausea (most common, typically transient)
- Diarrhea
- Vomiting
- Decreased appetite
- +3 more
- Stacks With
- —
- —